



January 15, 2023

**BSE Limited**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001**

✓ **National Stock Exchange of India Ltd.,**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051**

Dear Sir/Madam,

**Re: Disclosure pursuant to Regulation 30 of the SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Subject: U.S. FDA Inspection of the Company's Somerset manufacturing facility**

We would like to inform that the U.S. FDA inspected Lupin's Somerset, New Jersey, U.S.A. manufacturing facility from January 2, 2023 to January 13, 2023. The inspection closed with issuance of a Form-483 with two observations.

We are addressing the observations comprehensively and will work with the U.S. FDA to resolve these issues at the earliest. We uphold quality and compliance with utmost importance and are committed to be compliant with CGMP standards across all our facilities.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above is for your information and dissemination.

Thanking you,

Yours faithfully,  
**For LUPIN LIMITED**

**R. V. SATAM**  
**COMPANY SECRETARY**  
**(ACS -1 1973)**